NEW YORK (GenomeWeb) – Protein diagnostics firm Protagen has joined the UK-based Maximising Therapeutic Utility for Rheumatoid Arthritis (MATURA) consortium, through which it aims to develop a test for predicting patient response to therapy in RA.

The company hopes via its participation in the consortium to identify a subset of predictive markers from a current panel of 100 proteins it identified as possibly useful through previous studies of RA, Georg Lautscham, the company's chief business officer, told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.